Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. - Wikidata - awgldk - TriplyDB

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.

http://www.wikidata.org/entity/Q44786842

about

Mesenchymal stem cells avoid allogeneic rejection Proinflammatory stimuli induce galectin-9 in human mesenchymal stromal cells to suppress T-cell proliferation Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells.Bone marrow mesenchymal stem cell therapy in ischemic stroke: mechanisms of action and treatment optimization strategies Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future Current perspectives on the immunopathogenesis of systemic sclerosis Vascular Wall-Resident Multipotent Stem Cells of Mesenchymal Nature within the Process of Vascular Remodeling: Cellular Basis, Clinical Relevance, and Implications for Stem Cell Therapy Multipotent mesenchymal stromal cells: A promising strategy to manage alcoholic liver disease Toward Development of iMesenchymal Stem Cells for Immunomodulatory Therapy Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation Update on mesenchymal stem cell-based therapy in lupus and scleroderma The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity Mesenchymal Stromal Cells and Viral Infection Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients Mesenchymal Stromal Cells Affect Disease Outcomes via Macrophage Polarization Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells Mesenchymal stem cells, autoimmunity and rheumatoid arthritis Stromal cell-based immunotherapy in transplantation Immunological characteristics of human mesenchymal stem cells and multipotent adult progenitor cells Acquiring chondrocyte phenotype from human mesenchymal stem cells under inflammatory conditions Mesenchymal Stem Cells: Rising Concerns over Their Application in Treatment of Type One Diabetes Mellitus Human mesenchymal stromal cell-mediated immunoregulation: mechanisms of action and clinical applications Immunobiology of mesenchymal stem cells Immunotherapeutic potential of extracellular vesicles Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications Fetal fibroblasts and keratinocytes with immunosuppressive properties for allogeneic cell-based wound therapy Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology Mechanisms of mesenchymal stem/stromal cell function Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease Wharton's Jelly-Derived Mesenchymal Stromal Cells as a Promising Cellular Therapeutic Strategy for the Management of Graft-versus-Host Disease Immunogenicity of allogeneic mesenchymal stromal cells: what has been seen in vitro and in vivo?Perinatal immunotoxicity: why adult exposure assessment fails to predict risk Inflammation converts human mesoangioblasts into targets of alloreactive immune responses: implications for allogeneic cell therapy of DMD Characterization of the conditioned medium from amniotic membrane cells: prostaglandins as key effectors of its immunomodulatory activity

P2860

Q21245658-C955B64C-699F-4BA3-ABC7-17E226660177 Q24297200-B4B72D03-A406-4C54-BBB4-935ED7144FF8 Q24612869-43B185CD-5D6C-4BEA-B261-F2D401E6FF33 Q24632520-916F11D2-A6EB-4C54-89AC-3AEA68745353 Q24644691-D20C389A-B61D-4F5C-AE18-F6CDCBFC421D Q24681395-77ACD834-C6EF-4B14-BAEB-82A5451C3DB7 Q24812873-8176A809-8B61-44E5-A750-AD02D7697475 Q26740083-7926AAC5-1511-493A-8756-5BFCEEB5B953 Q26740490-75248CD1-E7D8-4174-BC75-7D44289A9C74 Q26741264-5027063B-90CC-4CDE-AB24-87CC5BCEACE4 Q26765919-206E7C7F-EDC9-4428-844C-58B62B9AE1B7 Q26769618-AAFB2C90-6231-4247-925B-1949B785EC23 Q26771451-606A1A79-5665-4A84-BC28-BCA154905A07 Q26775513-557D3D39-8627-451F-A885-ECECFAC58C6B Q26777402-85E1C717-C3DF-4705-AF34-2241F4F49134 Q26785900-FE6E7A4E-838B-4D8B-B040-16E73A5A03F5 Q26796198-EA0F5E0C-F66C-4D9B-BD1B-7EFF5ADB0379 Q26799916-AE8B30B3-3935-4609-8185-70FD484567F3 Q26800098-A8F0E237-2F2D-4240-978A-154733191FFC Q26801575-FA9C0303-7DBF-4BDF-B0DD-09D3516B9561 Q26822005-E24016C0-122F-4B5D-BA8D-D3A8FD9D6C01 Q26828950-51A77F93-3101-4957-BD26-0B598398C7A2 Q26851908-E5FD7BA5-CCC2-47E7-BE62-287DFE1F35BF Q26852467-DDD57C26-01DC-48F8-A218-CDC3A4AE06F0 Q26852836-4356F107-B262-4072-A547-F4E1A8BAE0D7 Q26864580-EBAA1421-7722-4D5A-8EA7-23BFF8ADADDB Q27004008-C8BDEACC-65F0-448E-BAA8-21E5EDA7EF40 Q27004487-9DD8BACC-DFC5-4C92-8150-99528D4F4861 Q27023323-97BB91C4-77CA-46C1-90B5-29DD56AD1408 Q27026892-4FC24EBA-BBBF-4196-82EB-A11F3FA28BB6 Q27310292-59D42207-C19D-4B0B-B6CC-C43A052314EE Q28072449-891E37C0-CE63-4CB0-BD39-58900FBC75D9 Q28077427-8C238524-3BAE-4816-8FC8-7BE4D0E30B14 Q28079649-BB712D8C-4F23-47B5-B714-C3F9356FE510 Q28081921-AB516020-01EB-4D3C-9650-F508288DFD59 Q28083027-C0F7CD69-328A-4714-B8FF-7D7347C80FD6 Q28084829-F5245EF2-3996-496D-B5C2-0CD1FA46EA77 Q28388168-4C7A6E59-0030-4A1C-8049-D75F9208DA22 Q28389778-1162B11C-D89C-428B-957C-EB501B19F4A8 Q28484341-54582455-AF8E-4967-B627-F06855EE979B

P2860

Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation.

http://www.wikidata.org/entity/Q44786842

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Human bone marrow stromal cell ...... diated tryptophan degradation.

@en

Human bone marrow stromal cell ...... diated tryptophan degradation.

@nl

type

label

Human bone marrow stromal cell ...... diated tryptophan degradation.

@en

Human bone marrow stromal cell ...... diated tryptophan degradation.

@nl

prefLabel

Human bone marrow stromal cell ...... diated tryptophan degradation.

@en

Human bone marrow stromal cell ...... diated tryptophan degradation.

@nl

P1433

Q44786842-AFF37636-6EB9-4EB8-88BA-9A8868448530

P1476

Q44786842-50873FB0-0095-453E-8997-46796DB34749

P2093

Q44786842-3020555E-B4F7-42A3-B12F-9946AB436CAA

Q44786842-7C345C8C-EFFA-42B8-AF88-483EF73E755F

Q44786842-8EAE6718-2289-464B-BF7C-03279D8D06E2

Q44786842-BF43AF0E-DD55-4D17-A3FE-0EBE586F1B57

Q44786842-DAB898ED-1F2B-4909-83A2-9EDB949FD5A9

P304

Q44786842-98C9EB23-5312-4C53-86AC-090DED9E7954

P31

Q44786842-E91B3EDC-B617-4D81-8BC0-7DAA9B10D61C

P356

Q44786842-3E210BDB-4ED5-41E1-8257-9EEA03B0979B

P407

Q44786842-90FE7908-562D-446B-AC49-397EA14E12EE

P433

Q44786842-6E92482D-B68C-4EB3-99AA-8A79F152DB13

P478

Q44786842-9E61C08B-19F1-4CAE-8B49-935836E202B7

P50

Q44786842-8AD4F5DA-64CC-4D35-AC53-4C51F166B749

P577

Q44786842-3B6CF3BC-0593-4726-9D4D-C103C02D3541

P5875

Q44786842-C39C1B7A-B2DD-461F-81BB-6B8F67B8AF1F

P698

Q44786842-4DF7F42F-62CB-4D8D-A8D2-4A048521F41A

P921

Q44786842-0B3A5BF3-E08F-46A0-83F7-C75410C983F3

P356

BLOOD-2003-11-3909

P1433

P1476

Human bone marrow stromal cell ...... diated tryptophan degradation.

@en

P2093

Dagmar Dilloo

http://www.w3.org/2001/XMLSchema#string

Maurice Laryea

http://www.w3.org/2001/XMLSchema#string

Roland Meisel

http://www.w3.org/2001/XMLSchema#string

Ulrich Göbel

http://www.w3.org/2001/XMLSchema#string

Walter Däubener

http://www.w3.org/2001/XMLSchema#string

P304

4619-4621

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2003-11-3909

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8488478

http://www.w3.org/2001/XMLSchema#string

P698

15001472

http://www.w3.org/2001/XMLSchema#string

P921